Rasha Aboelhassan: We can give TDM1 in stage I HER2 positive breast cancer
Rasha Aboelhassan shared a post on LinkedIn about a recent paper by Paolo Tarantino et al., commenting:
“Few years ago I met Safaa who was diagnosed as stage I HER2 positive breast cancer. She was not sad for her diagnosis but afraid of systemic therapy. She began her adjuvant therapy by trastuzumab and weekly paclitaxel.
Unfortunately she had grade III neuropathy after third week, even after dose reduction she had no improvement.
Today, after three years of ending her adjuvant therapy, she still have late neuropathy induced by paclitaxel.
Although that she was cured from breast cancer, her quality of life is not perfect.
This week I was so excited by the good news: we can give TDM1 not paclitaxel to stage I her2 positive breast cancer. Another good news, we can use HER2DX testing predict survival and responses to adjuvant therapy.”
Adjuvant Trastuzumab Emtansine Versus Paclitaxel Plus Trastuzumab for Stage I Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: 5-Year Results and Correlative Analyses From ATEMPT published in Journal of Clinical Oncology.
Authors: Paolo Tarantino, Nabihah Tayob, Guillermo Villacampa, Chau Dang, Denise A. Yardley, Steven J. Isakoff, Vicente Valero, Meredith Faggen, Therese Mulvey, Ron Bose, Douglas Weckstein, Antonio C. Wolff, Katherine Reeder-Hayes, Hope S. Rugo,, Bhuvaneswari Ramaswamy, Dan Zuckerman, Lowell Hart, Vijayakrishna K. Gadi, Michael Constantine, Kit Cheng, Audrey Merrill Garrett, P. Kelly Marcom, Kathy Albain, Patricia DeFusco, Nadine Tung, Blair Ardman, Rita Nanda, Rachel C. Jankowitz, Mothaffar Rimawi, Vandana Abramson, Paula R.Pohlmann, Catherine Van Poznak, AndresForero-Torres, Minetta C. Liu, Kathryn J. Ruddy, Adrienne G. Waks, Michelle DeMeo, BS, Harold J. Burstein,, Ann H. Partridge,, Patrizia Dell’Orto, ScD, Leila Russo, Emma Krause, Daniel J. Newhouse, Busem Binboğa Kurt, Elizabeth A. Mittendorf, Bryan Schneider, Aleix Prat, Eric P.Winer, Ian E. Krop, and Sara M. Tolaney.
Additional information
Source: Rasha Aboelhassan/LinkedIn
Rasha Aboelhassan is a Senior Oncology Consultant at Nasser Institute Hospital. In addition to her clinical role, she volunteers as a reviewer for the World Journal of Surgical Oncology, contributing to advancements in the field.